The global market for biosimilars has soared in recent years, driven by a push from healthcare systems across the world to take advantage of the savings that these products have to offer.
This market stood at over USD 15 billion in 2020, having grown at a CAGR of 56 percent since 2015. Moreover, McKinsey estimates that double digit biosimilar market growth is set to continue over the next decade, doubling to over USD 30 billion by 2025 and USD 60 billion by 2030. 17 blockbuster molecules with annual peak sales of over USD 60 billion will lose exclusivity between 2020 and 2025, allowing for greater biosimilars market entry.
This exclusive new PharmaBoardroom report, InFocus: Biosimilars 2022 provides a snapshot of this dynamic industry, with up-to-date infographics and datasets across market growth, market share, upcoming exclusivity expiries, FDA and EMA approvals, and leading companies.
Moreover, this report features the insights of some of the biosimilars industry’s most well-connected and insightful executives, providing their expert analysis on topics ranging from US market challenges to Europe’s crucial importance. Also profiled are both traditional innovator companies with burgeoning footprints in biosimilars as well as a growing cadre of pure play biosimilars/generics firms from nations as diverse as South Korea, Spain, and Turkey looking to differentiate themselves within this growing niche.